Jemperli becomes first anti-PD-1 therapy available for endometrial cancer in Europe

The European Commission has granted conditional marketing authorisation to GlaxoSmithKline (GSK) for Jemperli (dostarlimab), making it the first anti-PD-1 therapy available for endometrial cancer in Europe.

Jemperli is a programmed death receptor-1 (PD-1)-blocking antibody, for use in women with mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer who have progressed on or following prior treatment with a platinum containing regimen.

“Women with recurrent endometrial cancer, or advanced disease that has progressed on or after chemotherapy, currently have limited treatment options and a poor prognosis,” said Dr Hal Barron, Chief Scientific Officer and President R&D, GSK.

“Today’s approval of dostarlimab means that for the first time in Europe, these women will have access to a new, innovative and much-needed therapy.”

The European Medicine Agency’s approval is based on results from the multi-cohort GARNET study, which included women with recurrent or advanced dMMR/MSI-H endometrial cancer who progressed on or after a platinum-based chemotherapy regimen in cohort A1.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news